Key Highlights

  • Iovance Biotherapeutics (NASDAQ:IOVA) traded at USD 14.68 on October 28, 2026, up 34.93% over one month, down 1.77% over one week, up 224.06% over three months and up 428.06% year to date, per published market data.
  • Iovance Biotherapeutics (NASDAQ:IOVA) raised its 2026 revenue forecast on September 29, 2026 to USD 410 million to USD 420 million from USD 350 million to USD 370 million, and the shares hit their highest level in over two years.
  • Second quarter product revenue was a record USD 99.3 million, including USD 89.5 million from Amtagvi (lifileucel) and USD 9.8 million from Proleukin, and cash and investments were about USD 243 million.
  • Goldman Sachs resumed coverage with a Buy rating and a USD 15 target, and the shares at USD 14.68 sit about 2% below that target, simple arithmetic, after rising 428.06% year to date.

The Guidance Raise

On September 29, 2026 the company raised its full-year revenue forecast by USD 55 million at the midpoint, implying nearly 60% annual growth. It cited rising patient demand for Amtagvi and a manufacturing schedule that gives strong visibility into the third and fourth quarters. Second quarter product revenue was USD 99.3 million, a record. The implied price a month ago was about USD 10.88, simple arithmetic, which sits just before the September 29 jump, when the shares traded near USD 13.30. Iovance Biotherapeutics (NASDAQ:IOVA) has gained 224.06% over three months and 535.50% over one year. Amtagvi is a cell therapy for advanced melanoma, and each dose is manufactured for an individual patient, which makes capacity and logistics central to revenue.

Analyst Support and Pipeline

Goldman Sachs resumed coverage with a Buy rating and a USD 15 target on the view that launch-related operational and logistical challenges are easing and should support better gross margins. The company is running the TILVANCE-301 Phase 3 study of lifileucel with Keytruda in first-line advanced melanoma and has registrational programs in non-small cell lung cancer and endometrial cancer. Frederick Vogt serves as interim president and chief executive. Third quarter results are expected in early November 2026. The stock is down 1.77% over the past week, which suggests a pause after the surge. A Buy rating from a major broker can attract momentum buyers, but a single target is an opinion and the stock already trades near it.

Risks and What to Watch

A rise of 428.06% year to date leaves the stock vulnerable to profit-taking, and the price is close to the only target cited. The launch is still scaling, cash of about USD 243 million must fund a large clinical program and an interim chief executive adds leadership uncertainty. Manufacturing capacity and patient logistics could limit sales. Watch the early November report for third quarter revenue against the new USD 410 million to USD 420 million range, any update on a permanent chief executive and financing. This is not advice. Cell therapy launches can be uneven from quarter to quarter, and a miss against the raised range would likely hit a stock priced for execution.

Where Things Stand

The answer is that the September 29, 2026 guidance raise, backed by record Amtagvi sales and a Goldman Sachs Buy, explains the month. Iovance Biotherapeutics (NASDAQ:IOVA) gained 34.93% to USD 14.68, near the USD 15 target, after a 428.06% rise this year. Execution of the launch, cash needs and the interim chief executive are the risks. The report due in early November 2026 is the next test.